Multicentre Real-World Case-Control Study of Effectiveness, Tolerability, and Anti-Calcitonin Gene-Related Peptide Response Predictors in the Elderly-Reference-Cited by-同舟云学术

Multicentre Real-World Case-Control Study of Effectiveness, Tolerability, and Anti-Calcitonin Gene-Related Peptide Response Predictors in the Elderly

Published:2023-08-15 Issue: Volume: Page:49-51
ISSN:2054-4529
Container-title:EMJ Neurology
language:
Short-container-title:EMJ Neurol

Author:

Gonzalez-Martinez Alicia¹,Sanz-García Ancor²,Rodríguez-Vico Jaime Samuel³,Jaimes Alex³,García Andrea Gomez³,Limón Javier Casas⁴,de Terán Javier Díaz⁵,Sastre María⁵,Membrilla Javier⁵,Latorre Germán⁶,de Miguel Carlos Calle⁶,Quintas Sonia¹,Heredia Patricia¹,Luque Sendoa Gil⁷,Trevino-Peinado Cristina⁸,Echevarría Ana⁹,García-Azorín David⁹,Guerrero-Peral Ángel Luis⁹,Álvaro Sierra Álvaro Sierra⁹,González-García Nuria¹⁰,Porta Jesús¹⁰,Gago-Veiga Ana-Beatriz¹

Affiliation:

1. Headache Unit, Neurology Department, Hospital Universitario de la Princesa & Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain; Universidad Autónoma de Madrid, Spain

2. Data Analysis Unit, Hospital Universitario de la Princesa & Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain

3. Headache Unit, Neurology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

4. Headache Unit, Neurology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain

5. Hospital Universitario La Paz, Madrid, Spain

6. Headache Unit, Neurology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain

7. Headache Unit, Neurology Department, Hospital Universitario de Burgos, Castilla y León, Spain

8. Headache Unit, Neurology Department, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain

9. Headache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Castilla y León, Spain

10. Headache Unit, Neurology Department, Hospital Clínico San Carlos, Madrid, Spain

Publisher

European Medical Group

Subject

Cardiology and Cardiovascular Medicine

Reference11 articles.

1. Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-34.

2. Detke HC et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-21.

3. Silberstein SD et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113-22.

4. Dodick DW et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026-37.

5. Skljarevski V et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-54.